Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ikaria Inc.

www.ikaria.com

Latest From LifeCodexx AG

Molecular Diagnostics Ushers In New Era Of Prenatal Testing

The recent launch of several noninvasive gene-based tests for Down syndrome and other fetal chromosomal abnormalities is poised to upend current prenatal screening practices and potentially usher in a new, multibillion-dollar market opportunity in the process. These new tests employ next-generation gene sequencing, along with advanced, risk-based computer algorithms, to detect and characterize fetal genetic abnormalities using the DNA present in a maternal blood sample. And because they are actually able to “interrogate” the DNA, they represent a huge technological advance over the current standard-of-care for prenatal screening.

Medical Device Legal Issues

Deals Shaping the Medical Industry (10/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Deals Update

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Monitoring Equipment & Devices
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cardiovascular
  • Renal System
  • Respiratory, Pulmonary
  • Alias(es)
  • INO Therapeutics LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ikaria Inc.
  • Senior Management
  • Daniel Tasse, Chmn. & CEO
    Tasos G Konidaris, EVP, CFO & Corp. Dev.
    Douglas Greene, MD, EVP, CSO
    Stephen Ross, EVP, Chief Commerical Officer
  • Contact Info
  • Ikaria Inc.
    Phone: (908) 238-6600
    Perryville III Corp. Pk. 53 Frontage Rd.
    3rd Fl.
    P.O. Box 9001 Hampton, NJ 08827-9001
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register